Author

Georgina Paz-De la Rosa

Observed names: Georgina Paz De la Rosa, Georgina Paz-de la Rosa

Institutions: Universidad de Ciencias Médicas de Ciego de Ávila, Centro de Investigación Científica de Yucatán, A.C

Observed institutions: Universidad de Ciencias Médicas de Ciego de Ávila, Centro de Investigación Científica de Yucatán, A.C, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional

ORCID: 0000-0002-0491-9271

Observed ORCID: 0000-0002-0491-9271

OpenAlex ID: A5019948787

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

2023 · Samuel Ponce-de-León, Martha Torres, et al. · npj Vaccines · 72

Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs

2021 · Jesús Horacio Lara-Puente, Juan Manuel Carreño, et al. · mBio · 46

Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 “Patria” recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico

2024 · Constantino López-Macías, Martha Torres, et al. · Vaccine · 18

A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection

2011 · Alberto Monroy-García, Miguel A Gómez-Lim, et al. · Virology Journal · 15

Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine

2025 · Constantino López-Macías, Martha Torres, et al. · Science Advances · 6

Addressing SARS-CoV-2 evolution: neutralization of emerging variants of concern by the AVX/COVID-12 ‘Patria’ vaccine based on HexaPro-S ancestral Wuhan spike or its updated BA.2.75.2 version

2025 · Gregorio Carballo-Uicab, Gabriela Mellado-Sánchez, et al. · Frontiers in Immunology · 3

Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals

2024 · Alejandro Torres-Flores, Luis Alberto Ontiveros-Padilla, et al. · Frontiers in Immunology · 3

Phase II/III Double-Blind Study Evaluating Safety and Immunogenicity of a Single Intramuscular Booster Dose of the Recombinant SARS-CoV-2 Vaccine “Patria” (AVX/COVID-12) Using an Active Newcastle Disease Viral Vector (NDV) during the Omicron Outbreak in Healthy Adults with Elevated Baseline Antibody Titers from Prior COVID-19 and/or SARS-CoV-2 Vaccination

2024 · Constantino López-Macías, Martha Torres, et al. · medRxiv · 2

Works count: 8

Citation count: 165

H-index: 5

I10-index: 4